2022
Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies.
Zengin Z, Meza L, Malhotra J, Salgia S, Ely J, Hsu J, Kelley E, Mead H, Dizman N, Chehrazi-Raffle A, Govindarajan A, Muddasani R, Chawla N, Dorff T, Lyou Y, Karczewska E, Trent J, Salgia R, Altin J, Pal S. Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies. Journal Of Clinical Oncology 2022, 40: 185-185. DOI: 10.1200/jco.2022.40.6_suppl.185.Peer-Reviewed Original ResearchCOVID-19 vaccinationBlood samplesSystemic treatmentAntibody titersGenitourinary malignanciesSubset of ptsImmune checkpoint inhibitorsBaseline blood samplesLong-term efficacyAdditional blood samplesCOVID-19 vaccineSARS-CoV-2Short-term effectivenessCancer ptsSerologic outcomeCheckpoint inhibitorsGenitourinary cancersMedian ageTherapy cyclesBladder cancerTCR sequencingIgG ELISACoV-2Host immunityVaccination
2021
1564MO Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancers
Salgia S, Malhotra J, Zengin Z, Meza L, Ely J, Hsu J, Kelley E, Chehrazi-Raffle A, Govindarajan A, Muddasani R, Salgia N, Dizman N, Chawla N, Dorff T, Lyou Y, Karczewska E, Trent J, Salgia R, Altin J, Pal S. 1564MO Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancers. Annals Of Oncology 2021, 32: s1132. PMCID: PMC8454399, DOI: 10.1016/j.annonc.2021.08.1557.Peer-Reviewed Original Research